13vPnC + 23vPS
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vaccines, Pneumococcal Conjugate Vaccine
Conditions
Vaccines, Pneumococcal Conjugate Vaccine
Trial Timeline
Jan 18, 2010 → May 16, 2013
NCT ID
NCT00980655About 13vPnC + 23vPS
13vPnC + 23vPS is a phase 3 stage product being developed by Pfizer for Vaccines, Pneumococcal Conjugate Vaccine. The current trial status is completed. This product is registered under clinical trial identifier NCT00980655. Target conditions include Vaccines, Pneumococcal Conjugate Vaccine.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00980655 | Phase 3 | Completed |
Competing Products
20 competing products in Vaccines, Pneumococcal Conjugate Vaccine